Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update

Plaque Psoriasis: Seven-Market Drug Forecast and Market Analysis - Update

Summary

This publication is an update to the report Plaque Psoriasis: Global Drug Forecast and Market Analysis to 2030 (November 2021, GDHC232PIDR), which covered the forecast period 2020-30. This updated publication also covers the same forecast period.

GlobalData estimated the value of the global PsO market to be $11.6 billion across the 7MM in 2020. By 2030, PsO sales across are expected to grow to $31.7 billion, representing a compound annual growth rate (CAGR) of 10.6% over the 10-year forecast period.

Major drivers of growth in the PsO market over the forecast period include:

• Steady increase in total diagnosed prevalence across the 7MM
• Launches of seven new pipeline agents: SAR44156, JNJ-2113, sonelokimab, DC-806, orismilast, Piclidenoson, and TAK-279.
• Increased treatment options for mild and moderate patients, a historically undertreated population

The major barriers of growth in the PsO market during the forecast period include -

• Loss of patent protection in the US of biologics, such as Janssen’s Stelara (ustekinumab) in 2024 and Cosentyx in 2029, and the subsequent launches of their corresponding biosimilars
• Launch of apremilast generics in 2028 in the US
• Passage of the Inflation Reduction Act (IRA) and other legislature in the US aimed to reduce drug prices.

Key Highlights

• In 2022, GlobalData estimated that the global HF market reached $31.9 billion across the 7MM, and expects the HF market to grow at a strong Compound Annual Growth Rate of 5.2%, reaching sales of $53 billion by 2032.

Major drivers of HF market growth over the forecast period are the -

• Anticipated expanded indications for sodium-glucose co-transporter inhibitors.
• Launch of several oral and injectable agents.
• Increase in the global prevalence of chronic HF.

Scope

• Overview of PsO, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized PsO therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2020 to 2030.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PsO therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PsO treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global PsO therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM PsO therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM PsO therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Please note: this is delivered as a Zip file.